argenx SE is a clinical stage biotechnology company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Its product pipeline includes product candidates such as ARGX-111, ARGX-109, ARGX-115, ARGX-112, and others. The company operates in the Netherlands, Germany, Denmark, Belgium, Switzerland, the United States, and Luxembourg. It derives the majority of its revenues from Switzerland.
| Website: | www.argenx.com |
| Email: | info@argenx.com |
| Main Phone: | +31 763030488 |
| Address: | Willemstraat 5 |
| City / Town: | Breda |
| Country: | NL |
| Postal Code: | 4811 AH |
| Exchange: | GREY |
| CEO: | Tim Van Hauwermeiren |
| Employees: | 188 |
argenx SE is a clinical stage biotechnology company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Its product pipeline includes product candidates such as ARGX-111, ARGX-109, ARGX-115, ARGX-112, and others. The company operates in the Netherlands, Germany, Denmark, Belgium, Switzerland, the United States, and Luxembourg. It derives the majority of its revenues from Switzerland.
| Website: | www.argenx.com |
| Email: | info@argenx.com |
| Main Phone: | +31 763030488 |
| Address: | Willemstraat 5 |
| City / Town: | Breda |
| Country: | NL |
| Postal Code: | 4811 AH |
| Exchange: | GREY |
| CEO: | Tim Van Hauwermeiren |
| Employees: | 188 |
| Last Price 242.13 | Change $ 0. | Change % 0.00 | Tick N/A |
| Bid N/A | Bid Size 0.00 | Ask N/A | Ask Size 0.00 |
| Open N/A | High N/A | Low N/A | Prev Close 242.13 |
| Last Trade | Volume 0 | 52 Wk Hi 256.35 | 52 Wk Low 130.01 |
| Market Cap 11.4 bi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 47,108,499.00 | EPS (TTM) -2.29 | PE Ratio -27.80 | Exchange Greys |
© 2020 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait 